WallStSmart

Stryker Corporation (SYK)vsTrinity Biotech plc (TRIB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 40703% more annual revenue ($25.12B vs $61.55M). SYK leads profitability with a 12.9% profit margin vs -51.6%. TRIB appears more attractively valued with a PEG of 1.30. SYK earns a higher WallStSmart Score of 65/100 (C+).

SYK

Buy

65

out of 100

Grade: C+

Growth: 8.0Profit: 7.5Value: 9.3Quality: 7.0
Piotroski: 3/9Altman Z: 2.18

TRIB

Hold

37

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SYKUndervalued (+16.8%)

Margin of Safety

+16.8%

Fair Value

$393.59

Current Price

$327.65

$65.94 discount

UndervaluedFair: $393.59Overvalued

Intrinsic value data unavailable for TRIB.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SYK4 strengths · Avg: 8.8/10
EPS GrowthGrowth
55.9%10/10

Earnings expanding 55.9% YoY

Market CapQuality
$125.72B9/10

Large-cap with strong market position

Operating MarginProfitability
27.2%8/10

Strong operational efficiency at 27.2%

Free Cash FlowQuality
$1.88B8/10

Generating 1.9B in free cash flow

TRIB1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
18.1%8/10

18.1% revenue growth

Areas to Watch

SYK3 concerns · Avg: 3.7/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

P/E RatioValuation
39.1x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

TRIB4 concerns · Avg: 2.3/10
Market CapQuality
$15.89M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-19.1%2/10

ROE of -19.1% — below average capital efficiency

EPS GrowthGrowth
-77.3%2/10

Earnings declined 77.3%

Free Cash FlowQuality
$-77,1092/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : SYK

The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.

Bull Case : TRIB

The strongest argument for TRIB centers on Revenue Growth. Revenue growth of 18.1% demonstrates continued momentum. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bear Case : SYK

The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.

Bear Case : TRIB

The primary concerns for TRIB are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

SYK profiles as a value stock while TRIB is a growth play — different risk/reward profiles.

SYK carries more volatility with a beta of 0.87 — expect wider price swings.

TRIB is growing revenue faster at 18.1% — sustainability is the question.

SYK generates stronger free cash flow (1.9B), providing more financial flexibility.

Bottom Line

SYK scores higher overall (65/100 vs 37/100) and 11.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Trinity Biotech plc

HEALTHCARE · MEDICAL DEVICES · USA

Trinity Biotech plc acquires, develops, manufactures and markets medical diagnostic products for the clinical laboratory and point of care (POC) segments of the diagnostic market in the United States, Africa, Asia and Europe. The company is headquartered in Bray, Ireland.

Want to dig deeper into these stocks?